|:: Grants & Awards||p2|
|:: Business News||p3|
|:: Books & Journals||p4|
adaptiveoptics.org provides news and information for the world-wide adaptive optics community.
|London, U.K. – October 25, 2006: Optos plc, a leading medical technology company for the design, development, manufacturing and marketing of retinal imaging devices, today announced it has entered into a Licence Agreement with the University of Rochester that provides the Company with exclusive access to certain patents for using adaptive optics to improve the diagnostic capability and resolution of|
First used to refine the clarity of the most advanced telescopes enabling scientists to observe the furthest stars and galaxies, adaptive optics is now being applied to permit direct observation of individual living cells in the human body as may be observed through the eye.
Two of the world’s leading authorities in adaptive optics for vision science, Professor David R. Williams, Ph.D., Department of Brain and Cognitive Sciences, University of Rochester and Professor Austin Roorda, Ph.D., School of Optometry, University of California at Berkeley, have determined that adaptive optics may allow for the direct observation of the impact and effectiveness of emerging pharmaceutical therapies for the leading causes of blindness and certain, major systemic diseases, including diabetes, vascular and neurological disorders.
“We are excited about this new partnership for a number of reasons, not least of which is that Optos is
committed to routine screening of patients to detect
disease before irreparable damage to the retina has occurred and in time for therapeutic intervention,” said Professor David R. Williams.
“We believe that the ultra-high resolution of the images our adaptive optics technology
provides will allow the detection of some diseases even before standard clinical tests and before the patient experiences any symptoms. Optos’ approach is unique in the field of retinal imaging and will therefore allow the full benefit of adaptive optics to be realised.”
“Adaptive optics has the potential to significantly enhance our product offering and overall value proposition in helping eye and health care practitioners deliver state-of-the-art, efficient and altogether higher levels of clinical care to their patients,” said Allan Watson, Optos plc Interim CEO and Chief Financial Officer. “This agreement reflects our commitment to innovation and to maintaining a leading edge position in the field of retinal imaging.”
Under the terms of the agreement the commercial plan calls for product specification approval in December 2007 followed by product development in March 2009, pre-production in September 2010 and commercial market entry planned for September 2013.
|Full Press Release|
<<      >>